The Beauty Health Co.

As of May 10, 2023, The Beauty Health Co. is considered overvalued and risky, with poor financial metrics such as a Price to Book Value of 4.38 and negative ROCE and ROE ratios, despite a year-to-date return of 49.06% that underperformed the S&P 500's 12.22%.

As of May 10, 2023, The Beauty Health Co. is considered overvalued with negative financial metrics, including a P/E ratio of NA, a Price to Book Value of 4.38, and a return on equity of -94.21%, especially when compared to healthier peers like LeMaitre Vascular and MiMedx Group.

As of June 9, 2025, the market trend is mildly bearish, with daily moving averages indicating bearish sentiment, while mixed signals from weekly and monthly indicators suggest a cautious outlook.

The Beauty Health Co. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $70 million and a net loss of $10 million as of March 2025. It has a market cap of $192.80 million, with key metrics indicating significant financial challenges.

As of Jun 18, The Beauty Health Co. has a market capitalization of 192.80 million and reported net sales of 322.47 million with a net profit of -38.52 million over the latest four quarters. The balance sheet shows shareholder's funds of 51.80 million and total assets of 685.68 million.